Comparison of adherence between fixed and unfixed topical combination glaucoma therapies using Japanese healthcare/pharmacy claims database: A retrospective non-interventional cohort study

Chikako Shirai  
Pfizer Jpan Inc

Nobushige Matsuoka  
Pfizer Japan Inc

Toru Nakazawa  
ntoru@oph.med.tohoku.ac.jp  
https://orcid.org/0000-0002-5591-4155

Research article

Keywords: Adherence, persistence, glaucoma, fixed-combination eye drops, claims database, latanoprost

DOI: https://doi.org/10.21203/rs.3.rs-47479/v2

License: ☝️ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

**Background:** Adherence to chronic therapies is crucial to prevent the progression of disease, such as glaucoma. However, only a limited number of studies have investigated them using real-world data in Japan. This study aimed to evaluate Japanese patients’ adherence to fixed- and unfixed-combination eye drops as a second-line therapy for glaucoma in real-world practice.

**Methods:** This retrospective, non-interventional cohort study utilized a commercially available Japanese healthcare database (MinaCare database). Medical/pharmacy claims data were collected from 2011 to 2016. The primary endpoint was adherence to medications, assessed by proportion of days covered (PDC) with medication during a 12-month post-index period. Meanwhile, the secondary endpoints included the persistence rate.

**Results:** A total of 738 patients were included in this study: 309 and 329 in the fixed- and unfixed-combination cohorts, respectively. Prostaglandin analog (PG)/β-blocker (BB) was most commonly claimed in 241/309 (78.0%) patients in the fixed-combination cohort. In the unfixed-combination cohort, PG and BB were claimed in 130/329 (39.5%) patients, whereas PG and α2-agonist were claimed in 87/329 (26.4%) patients. Patients were more adherent to the fixed-combination than the unfixed-combinations (mean PDCs [SD], 79.1% [32.1] vs. 62.2% [38.0]; \(P < 0.0001\)). The proportion of patients with good adherence (PDC ≥ 80%) was also higher in the fixed-combination cohort (69.6%) than in the unfixed-combination cohort (48.6%) (\(P < 0.0001\)). During the 12-month post-index period, the persistence rate was higher in the fixed-combination cohort than in the unfixed-combination cohort (47.6% [95% confidence intervals (CI): 41.9–53.0] vs. 24.9% [95% CI: 20.4–29.7], \(P < 0.0001\)).

**Conclusions:** Japanese patients with glaucoma preferred the fixed-combination therapies over the unfixed-combination therapies. Hence, fixed-combination therapies would contribute to the improvement of adherence.

**Background**

Glaucoma is the most common causative disease of blindness in Japan.\(^1\) One of the critical risk factors for glaucoma is the intraocular pressure (IOP).\(^2\)\(^-\)\(^5\) IOP-lowering eye drops and surgeries, such as selective laser trabeculoplasty (SLT) and minimally invasive glaucoma surgery (MIGS), have been developed and used for treatment. Consequently, glaucoma has become manageable, provided that it is diagnosed early and the treatment is implemented in a timely manner to prevent the development and delay the progression of the disease.\(^6\)\(^,\)\(^7\) Recently a randomized study, called the LiGHT study, compared the clinical effectiveness as well as cost-effectiveness between the eye drops and the SLT groups and demonstrated that SLT is cost effective, suggesting that SLT should be offered as a first-line treatment for open-angle glaucoma and ocular hypertension.\(^8\) However, IOP-lowering eye drops still remain a first-line treatment option in many countries including Japan.
The treatment for glaucoma is generally started with a monotherapy, such as prostaglandin analogs (PG) or β-blockers (BB). If the first monotherapy is ineffective or intolerable, switching to another monotherapy is preferred. Whenever a monotherapy does not reach the target IOP or the target must be lowered as the disease progresses, a concomitant therapy with a medication that has a different mechanism of action should be considered. If such treatment regimens are successful, patients can avoid laser intervention and surgery. However, adherence to the therapy should be crucially improved for a successful glaucoma treatment, considering that nonadherence to glaucoma therapies has been a serious concern.

Risk factors for nonadherence to glaucoma therapies include patients’ problems (financial concern, poor understanding of the disease, and frequent eye drop application), healthcare providers’ issues (insufficient instruction/explanation and assessment of each patient’s conditions), and the relationship between patients and physicians (lack of communication and trust). A previous study reported that a fixed-combination therapy improved the long-term adherence of patients with glaucoma compared with the unfixed therapy. According to a nationwide survey performed in 2011–2012 in Japan using a questionnaire, good adherence to IOP-lowering eye drops was observed in 72.4% of patients. However, these risk factors and adherence rates were based on the data obtained from clinical studies under controlled conditions or an experimental setting. Therefore, patients’ adherence to the therapies should be investigated, and the risk factors in ordinary clinical settings should be determined using real-world data.

In several previous studies, adherence to glaucoma therapies was evaluated using pharmacy claims data. Unfortunately, to our knowledge, no such study has been conducted in Japan. Therefore, this study aimed to compare patients’ adherence between a fixed-combination therapy and an unfixed-combination therapy and to identify risk factors for nonadherence in Japanese patients with glaucoma by using a healthcare database.

**Methods**

**Study design**

This retrospective cohort study utilized a commercially available Japanese administrative healthcare database (MinaCare Co., Ltd., Tokyo, Japan) to investigate the adherence of patients to fixed-combination and unfixed-combination therapies for glaucoma treatment after switching from a monotherapy. The study consisted of a 12-month pre-index period, an index date (defined as a first prescription day of either when a single eye drop was first switched to a fixed-combination therapy [fixed-combination cohort] or when the second eye drop was added to a single eye drop initially [unfixed-combination cohort]), and a 12-month post-index period. Patients without claims for 12 months after the index date and those who claimed the third drug in addition to a fixed-combination therapy or in addition to an unfixed-combination therapy indicated withdrawal. Approval for this research by an ethical review committee and informed consent of each subject were not required because studies using only unlinkably anonymized data are outside the scope of “Ethical Guidelines for Medical and Health Research Involving Human Subjects” set by the Japanese government.
Data source and study cohort

The MinaCare database includes anonymized data on both health checkup and medical/pharmacy claims of workers and their family members in a wide range of age groups below the age of 75 years. Maintained by MinaCare Co., Ltd., this database is updated periodically with newly available data obtained from the employment-based health insurance groups. It includes the data of 6.3 million uniquely identified individuals as of April 2017 and has recorded the information of 1.8 million patients from April 2016 to March 2017, covering 1.7% of the Japanese population under the age of 75 years. Furthermore, it is generally consistent with two national databases and is useful as it has low selection bias and large sample size with wide age distribution; however, it only targets national-wide big corporations, such as manufacturing, food, information transportation, and energy industries, and does not include individuals in the primary industry (agriculture, fisheries, forestry, etc.) or those who are self-employed.

Patients were extracted from the database with the ICD10 diagnosis codes H401 (normal tension glaucoma, primary open-angle glaucoma, and open-angle glaucoma) and H409 (unspecified glaucoma) and with prescription claims for the eye drops to treat glaucoma between April 1, 2011 and March 31, 2016. We included those who had received monotherapy for 1 year or longer without surgery including laser treatment and then switched to a fixed-combination therapy as second-line treatment (the fixed-combination cohort) or those who received an additional eye drop, such as timolol as an addition to latanoprost or vice versa, as second-line treatment (the unfixed-combination cohort). The first prescription date of the second-line therapy was defined as the index date. Patients without prescription of a fixed or unfixed-combination therapy, with history of surgery or laser surgery for glaucoma, or with pre-index monotherapy for <12 months were excluded.

Study endpoints

The primary endpoint was medication adherence, which was assessed by the proportion of days covered (PDC) with medication over the 12-month post-index period. The a priori definition of adherence cutpoint was 80%. Meanwhile, the secondary endpoints were related to medication persistence, defined as the act of continuing the use of claimed eye drops, and included persistence rate and its duration, a distribution of patients according to the type of claimed eye drops at the index date and switching patterns of eye drops during the 12-month post-index period. In addition, the risk factors for PDC < 80% were analyzed.

Assessments

Subject background characteristics included sex, age, body weight, height, body mass index, smoking status/history, health examination results, comorbidity, residence region, the number of eye drop bottles consumed, and eye drop types. These characteristics were summarized in all patients and in each cohort. Moreover, residence regions were classified into eight regions from Hokkaido to Kyushu including Okinawa, two areas (East Japan vs. West Japan), and city sizes (big cities including Tokyo and 20
ordinance-designated cities vs. the others). We also identified the PDC over 12 months after the index date in all patients and each cohort, the risk factors for PDC < 80%, and the persistence rate.

To address the possible variations in the dosage and prescribed period reported on a claim for glaucoma medication, we made adjustments based on the unit volume of the formulation. For example, if the dosage was “7.5” and the period was “1” in a claim, we converted them to “2.5 mL (approved bottle) × 3 bottles” prescribed for 3 months because one bottle (2.5 mL for once-daily formulations or 5 mL twice-or-more-daily formulations) is enough to apply one eye for more than 30 days but is correspondent to 30 days dispensed. The general recommendation of the use-by period of opened eye drop bottles is generally 4 weeks in Japan. Accordingly, the patients were permitted a 30-day grace period to obtain the next prescription. In addition, if one prescription consists of ≥7 bottles, the patient was considered receiving treatment of both eyes. Therefore, a PDC value was calculated using the following formula:

\[ \text{PDC} \% = \left( \frac{\text{total prescription days during the 365-day assessment}}{365 \text{ days}} \right) \times 100 \]

In this study, the PDC is calculated according to the period only prescribed with two-drug fixed-combination drops or two-drug unfixed-combination therapies, regardless of switching drug class [e.g., PG+BB to PG+ carbonic anhydrase inhibitor (CAI)].

Persistence refers to the act of continuing index therapy (i.e., a fixed-combination therapy or an unfixed-combination therapy). The definition of “persistence” is the duration in days from the index date (the first prescription date of the index therapy) to the last prescription date + prescription days or to the discontinuation date allowing a 30-day grace period. In the case of one drug addition to the combination of two drugs (e.g., PG+BB to PG+BB+AA), it was considered as “discontinued/withdrawn.” Likewise, in a subset analysis using specific drug classes, no prescription record for more than 30 days or switched or changed prescriptions were treated as “discontinued.” The cumulative discontinuation rate was analyzed based on the time to discontinuation and was estimated using the Kaplan–Meier method. Patients who continued the treatment for 12 months were treated as censored at 12 months. The persistence rate at the evaluated time point was calculated as follows:

\[ \text{Persistence rate} \% = 100\% - \text{cumulative discontinuation rate} \]

Statistical analysis

We presented summary statistics (mean and standard deviation [SD] or a number and a proportion of patients) for the patients’ background characteristics and PDC. Using t-test, we compared the mean PDC values between two cohorts. Furthermore, proportions of patients with or without ≥80% PDC between two cohorts were compared using Pearson's \( \chi^2 \) tests. Bonferroni correction was used to adjust for multiplicity (m = 9, where m is the total number of statistical tests in this study). A p-value <= 0.00556 (0.05 / 9) was considered statistically significant for comparisons between the groups. We also explored the risk factors for nonadherence to the medications (PDC < 80%) by using a univariate logistic regression model. Subsequently, multivariate analyses were performed for those with \( P < 0.1 \), followed by a stepwise
(forward and backward) logistic regression model. The odds ratios (OR) and Wald 95% confidence intervals (CIs) were presented. The subject persistence rates at 6 and 12 months with a pointwise 95% CI were estimated using the Kaplan–Meier method, and the differences between the two treatment cohorts were tested by log-rank test. All the statistical analyses were performed using the SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).

Results

In total, 57,899 patients were diagnosed with glaucoma and prescribed with any IOP-lowering drug in the database, of whom 309 patients were in the fixed-combination cohort and 329 patients were in the unfixed-combination cohort (Fig. 1). The two cohorts had similar baseline demographic and clinical characteristics (Table 1). The mean age was 56–57 years and clinical measurement values were within the normal ranges. Comorbidities reported in >20% of patients were hypertension, hyperlipidemia, diabetes mellitus, and cancer. In both cohorts, over 80% of patients lived in East Japan (especially residents of Tokyo or large cities).

The eye drops claimed at the index date are summarized in Fig. 2. In the fixed-combination cohort, PG/BB (78.0%) and CAI/BB (22.0 %) were used by drug class, and the most commonly used eye drop was latanoprost/timolol (39.8%) by generic name. In the unfixed-combination cohort, the top three most frequently administered drug combinations were PG+BB (39.5%), PG+α2-agonist (AA) (26.4%), and PG+CAI (14.3%) by drug class; the most common drugs were latanoprost and brimonidine (12.2%), followed by latanoprost and timolol (11.9%) by generic name.

Common patterns of switching eye drops during the post-index period are shown in Fig. 3. In the fixed-combination cohort, out of 241 patients prescribed with PG/BB, 165 (68.5%) continued the same drug class, and out of 68 patients prescribed with CAI/BB, 38 (55.9%) continued the same drug class. Other major switching patterns were the addition of AA or CAI. In the unfixed cohort, the same drug class combination therapies were continued by only less than 50% of patients, regardless of the kind of combination.

The mean PDC over the 12-month post-index period was 70.4% in all the patients, 79.1% in the fixed-combination cohort, and 62.2% in the unfixed-combination cohort; hence, the PDC in the fixed-combination cohort was significantly higher than that in the unfixed-combination cohort ($P < 0.0001$) (Table 2). High adherence (PDC $\geq 80\%$) was observed in 58.8% of all the patients, 69.6% in the fixed-combination cohort, and 48.6% in the unfixed-combination cohort; hence, it was significantly higher in the fixed-combination cohort than in the unfixed-combination cohort ($P < 0.0001$). As for the popular combination of latanoprost and timolol, the mean PDC was 82.9% in the fixed-combination cohort and 66.5% in the unfixed-combination cohort; hence, it was higher in the fixed-combination cohort ($P = 0.0191$) (Table 3), but it was not significant (NS). A proportion of patients with PDC $\geq 80\%$ was 75.6% in the fixed-combination cohort and 53.8% in the unfixed-combination cohort, showing that it was higher in the fixed-combination cohort ($P = 0.0095$, NS). Furthermore, when compared between the PG/BB and
CAI/BB of the same fixed-combination cohort, PG/BB had an approximately 10% higher mean PDC value \((P = 0.0438, \text{NS})\) and an approximately 15% higher proportion of patients with good adherence \((P = 0.0131, \text{NS})\) (Table 4).

Univariate analyses identified treatment (fixed-combination vs. unfixed-combination) and hemoglobin A1c (HbA1c) as potential risk factors for nonadherence \((P < 0.1)\) (Table 5). Conversely, variables, such as age, sex, body mass index, smoking habit, hospital locations, and comorbidities, were not associated with nonadherence. In multivariate analyses, treatment (adjusted OR: 0.388 [95% CI: 0.259, 0.583], \(P < 0.0001\)) and HbA1c (adjusted OR: 1.606 per 1% [95% CI: 1.105, 2.333], \(P = 0.0130\)) were also considered as significant risk factors.

Kaplan–Meier curves of persistence are presented in Fig. 4A. According to nonoverlapping 95% CIs, more patients in the fixed-combination cohort than in the unfixed cohort continued their treatment after 2 months post-index, with a significant difference between the two cohorts (log-rank test, \(P < 0.0001\)). The persistence rates at 6 and 12 months post-index were approximately 67.6% (95% CI: 62.1, 72.5) and 47.6% (95% CI: 41.9, 53.0), respectively, in the fixed-combination cohort, and 48.0% (95% CI: 42.5, 53.3) and 24.9% (95% CI: 20.4, 29.7), respectively, in the unfixed-combination cohort.

Likewise, the persistence rate of the fixed-combination therapy with latanoprost and timolol was significantly higher than that of the unfixed-combination cohort (log-rank test, \(P = 0.0001\)) (Fig. 4B). Persistence rates at 6 and 12 months post-index were approximately 74.0% (95% CI: 65.3, 80.3) and 54.5% (95% CI: 45.3, 62.8), respectively, in the latanoprost/timolol fixed-combination cohort and 46.2% (95% CI: 30.2, 60.7) and 25.6% (95% CI: 13.3, 39.9), respectively, in the counterpart cohort.

Additionally, when compared between classes of the fixed-combination therapies, that is, PG/BB vs. CAI/BB, at 12 months post-index, the persistence rate of the PG/BB group was approximately 8% higher than that of the CAI/BB group (49.4% [95% CI: 42.9, 55.5] vs. 41.2% [95% CI: 29.5, 52.5]). However, it remained to be not statistically significant (log-rank test, \(P = 0.1454\)) (Fig. 4C).

**Discussion**

The present study found that patients with fixed-combination therapy adhered to their therapies better than those with unfixed-combination therapy after switching from at least 12 months of monotherapy to a combination therapy with two drugs. Our findings are clinically important because no comparative study of adherence and persistence between fixed and unfixed-combination therapies has been reported in Japanese patients with glaucoma by using real-world data.

Most of the patients were prescribed with a combination of PG and BB in accordance with the guideline recommendation. Overall, good adherence (PDC \(\geq 80\%\)) was noted in 58.8% of patients, lower than the results (72.4%) of a nationwide survey using a questionnaire in Japan. In the fixed-combination cohort, 47.6% of patients continued the two-drug combination drugs at 12 months post-index, and 69.6% showed good adherence during the 12 months. Patients receiving a fixed-combination also had a higher 12-
month persistence rate. The persistence rate of latanoprost/timolol fixed-combination was as high as 54.5%. Otherwise, most patients continued treatment using the same drops or the same class of drops, or switched to add-on therapy with the third drug (AA or CAI), suggesting that a fixed-combination was preferred. Although not significant, the PG/BB type had a slightly higher persistence rate than the CAI/BB type. Meanwhile, in the unixed-combination cohort, only approximately 50% of the patients had good adherence. Furthermore, only 24.9% stayed on the unixed two-drug combination therapy at 12 months post-index. Of note, the persistence rate of unixed latanoprost plus timolol was as low as 25.6%. Therefore, if eye drops had the same combination, the fixed-combination therapy would achieve high adherence and persistence.

The major reason for the high adherence of the fixed combination therapy may be because they are more convenient for patients. An interval of 5 minutes or more is required when two ophthalmic solutions are used in unixed combination eye drops, whereas two types of eye drops can easily be administered using a single eye drop in fixed combination drugs. Moreover, the number of eye drops and applications in fixed combinations are very small. Furthermore, to reduce the physical and economic burden on patients, physicians should explain to patients that the use of the fixed-combination therapies is advantageous because it requires less frequent medication and decreased exposure to preservatives (decreased risk of developing ocular surface diseases)\(^3^0,3^1\) with similar efficacies,\(^1^5,3^2-3^4\) or possibly superior in daily practice,\(^3^5\) compared with unixed-combination therapies. In an overseas clinical study, patients can better adhered with fixed-combination therapies than with unixed-combination therapies.\(^1^5\) Considering that good adherence to therapies is critical for controlling glaucoma progression,\(^9,3^6,3^7\) we believe that a fixed-combination therapy is an advantageous option for glaucoma treatment.

Given that the analyzed patients had received eye drop monotherapy for at least 1 year and continued to visit hospitals, they seemed to have been educated by doctors and have possibly understood the importance of continuing treatment with eye drops. However, many patients were nonadherent to the index therapy. In fact, an unixed-combination therapy was consistently a risk factor for adherence. Furthermore, a high HbA1c level, but not diabetes mellitus, was another risk factor for nonadherence to the treatment. Considering the small sample size and numerous missing data, HbA1c is carefully concluded as a risk factor. However, diabetic patients with higher HbA1c levels are apt to be nonadherent to the therapy because a higher HbA1c level; i.e., poor glycemic control can be partly explained by poor adherence to antidiabetic medications and medical visits.\(^3^8-4^1\) Type 2 diabetes mellitus, as well as glaucoma, is a chronic disease in which patients may have few symptoms despite having complex medication. If patients have complications, they need to take more pills at different times as per medicine. These patients may pay minimal attention to eye drops, leading to glaucoma progression. Therefore, glaucoma should be treated with continuous intervention in patients with diabetes mellitus, especially patients with poor glycemic control.

Moreover, other common risk factors were previously identified.\(^1^2-1^4\) All of these risk factors need to be solved by education, communication with patients, and patient training in improving proficiency of self-
administration of eye drops.42

Specific reasons on why physicians prescribed unfixed combinations for certain patients would be interesting to identify. Such reasons may include a risk of adverse events caused by the concentration of the fixed-combination, preservative formulations, and dosage adjustment of eye drops. If so, developing a new fixed-combination therapy would be worthwhile.

This study, however, has limitations. First, this study assumes that patients took eye drops for the number of days that they were prescribed, because the claims database does not track whether the patient actually administrated the eye drops as prescribed. However, we set a 30-day grace period so that the PDC did not underestimate adherence. Second, the study did not consider baseline PDC in patients that had been continuing monotherapy for 12 months prior to the index date, although baseline may or may not differ between the groups. Third, we used the MinaCare database to gather healthcare information covering nearly 2 million individuals, of which 90% were aged 20–59 years who worked for a nationwide large company, of which, most individuals lived in Tokyo or large cities in East Japan, and their dependents in private corporate health insurance societies.24,25 Therefore, regional and income biases might have affected the results. Moreover, only few elderly patients were included in this study. However, this study is worth considering for treating glaucoma because young patients are more likely to have glaucoma progression during their long life-spans. Fourth, the patients between the two cohorts possessed an uncontrolled nature, which includes the numerous drug types used as monotherapy during the pre-index period and the severity of glaucoma. Although background information and baseline characteristics were limited, they were similar between the two cohorts. Finally, the present analyses were built according to the assumption that all of the claimed drugs were used by the patients. To address these limitations, we need to conduct further studies using the real-world data combined with clinical data.

Conclusions

The present results using the real-world data showed that city patients who received fixed-combination therapies exhibited better adherence to medications compared with those who received unfixed-combination therapies. A high HbA1c level was one risk factor for nonadherence. Therefore, a fixed-combination therapy would better serve as a glaucoma therapy, considering that adherence to the therapy is a key for effectively preventing glaucoma progression.

Abbreviations

AA: α2-agonist; BB, β-blocker; CAI: carbonic anhydrase inhibitor; CI: confidence interval; HbA1c: hemoglobin A1c; IOP: intraocular pressure; MIGS: minimally invasive glaucoma surgery; NS: not significant; OR: odds ratio; PDC: proportion of days covered; PG: prostaglandin analog; SD: standard deviation; SLT: selective laser trabeculoplasty.
Declarations

*Ethics approval and consent to participate*

This study used subject-level electronic health related databases that protected the identity of the individuals. MinaCare is allowed to use such anonymized data under the data transfer contract with its client health insurers. Although this study is outside the scope of the guidelines because the data is protected by anonymization, we referred to the “Ethical Guidelines for Epidemiological Research” laid down by the Japanese government [23].

*Consent for publication*

Not applicable.

*Availability of data and materials*

The data that support the findings of this study are available from MinaCare but restrictions apply to the availability of these data, which were used under license for the current study. Therefore, the data are not publicly available. The data are however available from the authors upon reasonable request and with the permission of MinaCare.

*Competing interests*

Chikako Shirai is a full-time employee of Pfizer Japan Inc. Nobushige Matsuoka is a full-time employee of Pfizer R&D Japan G.K. Toru Nakazawa is a Professor of Tohoku University Graduate School of Medicine and has no conflicts of interest associated with this manuscript.

*Funding*

This study was financially supported by Pfizer Japan Inc.

*Authors' contributions*

CS, NM and TN were involved in the conceptual development and study design. NM performed the statistical analyses. All authors participated in the interpretation of the data and in drafting and/or revising the manuscript critically for developing important intellectual content. All authors gave their final approval to the manuscript to be submitted.

*Acknowledgments*

This study was financially supported by Pfizer Japan Inc. The authors are grateful to Yuji Yamamoto, M.D., M.B.A., MinaCare Co., Ltd for supplying data for this study. We also thank medical writer Takahiko Murata, Ph.D., WysiWyg Co., Ltd. for his assistance in the preparation of this manuscript.
References

1. Morizane, Y., Morimoto, N., Fujiwara, A., et al. Incidence and causes of visual impairment in Japan: the first nation-wide complete enumeration survey of newly certified visually impaired individuals. *Jpn J Ophthalmol*. 2019;63:26-33.

2. Coleman, A.L., and Kodjebacheva, G. Risk factors for glaucoma needing more attention. *Open Ophthalmol J*. 2009;3:38-42.

3. Cohen, L.P., and Pasquale, L.R. Clinical characteristics and current treatment of glaucoma. *Cold Spring Harb Perspect Med*. 2014;4:a017236.

4. Kastner, A., and King, A.J. Advanced glaucoma at diagnosis: current perspectives. *Eye (Lond)*. 2020;34:116-128.

5. Lee, J.W.Y., Chan, P.P., Zhang, X., Chen, L.J., and Jonas, J.B. Latest developments in normal-pressure glaucoma: diagnosis, epidemiology, genetics, etiology, causes and mechanisms to management. *Asia Pac J Ophthalmol (Phila)*. 2019;8:457-468.

6. Kass, M.A., Heuer, D.K., Higginbotham, E.J., et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. *Arch Ophthalmol*. 2002;120:701-713; discussion 829-830.

7. Leske, M.C., Heijl, A., Hussein, M., et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. *Arch Ophthalmol*. 2003;121:48-56.

8. Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. *Lancet*. 2019;393(10180):1505-1516.

9. The Japan Glaucoma Society Guidelines for Glaucoma (4th Edition) (in Japanese).: [http://www.nichigan.or.jp/member/guideline/glaucoma4.pdf](http://www.nichigan.or.jp/member/guideline/glaucoma4.pdf). Accessed 22 Jul 2020.

10. Wolfram, C., Stahlberg, E., and Pfeiffer, N. Patient-reported nonadherence with glaucoma therapy. *J Ocul Pharmacol Ther*. 2019;35:223-228.

11. Meier-Gibbons, F., Berlin, M.S., and Töteberg-Harms, M. Influence of new treatment modalities on adherence in glaucoma. *Curr Opin Ophthalmol*. 2019;30:104-109.

12. Tsai, J.C., McClure, C.A., Ramos, S.E., Schlundt, D.G., and Pichert, J.W. Compliance barriers in glaucoma: a systematic classification. *J Glaucoma*. 2003;12:393-398.

13. Newman-Casey, P.A., Robin, A.L., Blachley, T., et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. *Ophthalmology*. 2015;122:1308-1316.

14. Robin, A.L., and Muir, K.W. Medication adherence in patients with ocular hypertension or glaucoma. *Expert Rev Ophthalmol*. 2019;14:199-210.

15. Barnebey, H.S., and Robin, A.L. Adherence to fixed-combination versus unfixed travoprost 0.004%/timolol 0.5% for glaucoma or ocular hypertension: a randomized trial. *Am J Ophthalmol*. 2017;176:61-69.
16. Tsumura, T., Kashiwagi, K., Suzuki, Y., et al. A nationwide survey of factors influencing adherence to ocular hypotensive eyedrops in Japan. *Int Ophthalmol*. 2019;39:375-383.

17. Nordstrom, B.L., Friedman, D.S., Mozaffari, E., Quigley, H.A., and Walker, A.M. Persistence and adherence with topical glaucoma therapy. *Am J Ophthalmol*. 2005;140:598-606.

18. Friedman, D.S., Quigley, H.A., Gelb, L., et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the glaucoma adherence and persistency study (GAPS). *Invest Ophthalmol Vis Sci*. 2007;48:5052-5057.

19. Yeaw, J., Benner, J.S., Walt, J.G., Sian, S., and Smith, D.B. Comparing adherence and persistence across 6 chronic medication classes. *J Manag Care Pharm*. 2009;15:728-740.

20. Campbell, J.H., Schwartz, G.F., LaBounty, B., Kowalski, J.W., and Patel, V.D. Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions. *Clin Ophthalmol*. 2014;8:927-935.

21. Tse, A.P., Shah, M., Jamal, N., and Shaikh, A. Glaucoma treatment adherence at a United Kingdom general practice. *Eye (Lond)*. 2016;30:1118-1122.

22. Sheer, R., Bunniran, S., Uribe, C., et al. Predictors of nonadherence to topical intraocular pressure reduction medications among medicare members: a claims-based retrospective cohort study. *J Manag Care Spec Pharm*. 2016;22:808-817a.

23. The Ministry of Education, Culture, Sports, Science and Technology of Japan, the Ministry of Health, Labour and Welfare of Japan. Ethical guidelines for medical and health research involving human subjects.: https://www.mhlw.go.jp/le/06-Seisakujouhou-10600000-Daijinkanboukouseikagakuka/0000080278.pdf. Accessed 22 Jul 2020.

24. Shima, D., Li, Y., Yamamoto, Y., et al. A retrospective, cross-sectional study of real-world values of cardiovascular risk factors using a healthcare database in Japan. *BMC Cardiovasc Disord*. 2014;14:120.

25. Yuasa, A., Murata, T., Imai, K., Yamamoto, Y., and Fujimoto, Y. Treatment procedures and associated medical costs of methicillin-resistant *Staphylococcus aureus* infection in Japan: a retrospective analysis using a database of Japanese employment-based health insurance. *SAGE Open Med*. 2019;7:2050312119871181.

26. Pharmacoepidemiology & Database Taskforce, Japanese Society for Pharmacoepidemiology. Databases available for pharmacoepidemiology researches in Japan (information obtained from suvey answers as of August 2019): http://www.jspe.jp/mt-static/FileUpload/files/JSPE_DB_TF_E.pdf. Last accessed on May 13, 2020.

27. The Ministry of Foreign Affairs of Japan (MOFA). Regions of Japan Kid Web Japan: https://web-japan.org/kidsweb/explore/regions/index.html. Accessed 22 Jul 2020.

28. Asahi Net Home Page.: https://asahi-net.jp/en/service/ftth/withflets/index_area.html. Accessed 22 Jul 2020.

29. Council of Local Authorities for International Relations (CLAIR). 2012 Local government in Japan.: http://www.clair.or.jp/j/forum/pub/pdf/jichi12_en.pdf. Accessed 22 Jul 2020.
30. Rosin, L.M., and Bell, N.P. Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops. *Clin Ophthalmol.* 2013;7:2131-2135.

31. Asiedu, K., and Abu, S.L. The impact of topical intraocular pressure lowering medications on the ocular surface of glaucoma patients: a review. *J Curr Ophthalmol.* 2019;31:8-15.

32. Zhao, J.L., Ge, J., Li, X.X., et al. Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension. *BMC Ophthalmol.* 2011;11:23.

33. Bhagat, P., Sodimalla, K., Paul, C., et al. Efficacy and safety of benzalkonium chloride-free fixed-dose combination of latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. *Clin Ophthalmol.* 2014;8:1241-1252.

34. Nagayama, M., Nakajima, T., and Ono, J. Safety and efficacy of a fixed versus unfixed brinzolamide/timolol combination in Japanese patients with open-angle glaucoma or ocular hypertension. *Clin Ophthalmol.* 2014;8:219-228.

35. Lanzl, I., and Raber, T. Efficacy and tolerability of the fixed combination of brinzolamide 1% and timolol 0.5% in daily practice. *Clin Ophthalmol.* 2011;5:291-298.

36. Broadway, D.C., and Cate, H. Pharmacotherapy and adherence issues in treating elderly patients with glaucoma. *Drugs Aging.* 2015;32:569-581.

37. Atey, T.M., Shibeshi, W., Giorgis, A.T., and Asgedom, S.W. The impact of adherence and instillation proficiency of topical glaucoma medications on intraocular pressure. *J Ophthalmol.* 2017;2017:1683430.

38. Nagrebetsky, A., Griffin, S., Kinmonth, A.L., et al. Predictors of suboptimal glycaemic control in type 2 diabetes patients: the role of medication adherence and body mass index in the relationship between glycaemia and age. *Diabetes Res Clin Pract.* 2012;96:119-128.

39. Feldman, B.S., Cohen-Stavi, C.J., Leibowitz, M., et al. Defining the role of medication adherence in poor glycemic control among a general adult population with diabetes. *PLoS One.* 2014;9:e108145.

40. Lin, L.K., Sun, Y., Heng, B.H., Chew, D.E.K., and Chong, P.N. Medication adherence and glycemic control among newly diagnosed diabetes patients. *BMJ Open Diabetes Res Care.* 2017;5:e000429.

41. García Díaz, E., Ramírez Medina, D., García López, A., and Morera Porras, Ó.M. Determinants of adherence to hypoglycemic agents and medical visits in patients with type 2 diabetes mellitus. *Endocrinol Diabetes Nutr.* 2017;64:531-538.

42. Feng, A., O'Neill, J., Holt, M., et al. Success of patient training in improving proficiency of eyedrop administration among various ophthalmic patient populations. *Clin Ophthalmol.* 2016;10:1505-1511.

Tables

Table 1. Baseline demographic and clinical characteristics of subjects
| Variable                              | Fixed combination (N = 309) | Unfixed combination (N = 329) |
|--------------------------------------|----------------------------|-------------------------------|
|                                      | n                          | Percentage or mean ± SD       | n                          | Percentage or mean ± SD |
| Sex, male                            | 170                        | 55.0                          | 188                       | 57.1                      |
| Age (years)                          | 309                        | 56.5 ± 10.2                   | 329                       | 57.1 ± 10.2               |
| Body weight (kg)                     | 210                        | 61.8 ± 12.5                   | 219                       | 61.6 ± 11.0               |
| Height (cm)                          | 218                        | 163.9 ± 9.2                   | 226                       | 164.4 ± 8.9               |
| Body mass index (kg/m²)              | 210                        | 22.9 ± 3.5                    | 219                       | 22.7 ± 3.1                |
| Smoking                              |                            |                               |                           |                           |
| Yes                                  | 33                         | 10.7                          | 32                        | 9.7                       |
| No                                   | 178                        | 57.6                          | 193                       | 58.7                      |
| Medication for other indications     |                            |                               |                           |                           |
| Yes                                  | 63                         | 20.4                          | 74                        | 22.5                      |
| No                                   | 146                        | 47.2                          | 149                       | 45.3                      |
| Fasting blood glucose (mg/dL)        | 200                        | 97.0 ± 17.4                   | 213                       | 97.8 ± 15.4               |
| HbA1c (NGSP) (%)                     | 205                        | 5.6 ± 0.6                     | 216                       | 5.6 ± 0.5                 |
| Urine glucose                        |                            |                               |                           |                           |
| Negative (−)                         | 208                        | 67.3                          | 221                       | 67.2                      |
| Positive (≥±)                        | 4                          | 1.3                           | 2                         | 0.6                       |
| Urine protein                        |                            |                               |                           |                           |
| Negative (−)                         | 192                        | 62.1                          | 207                       | 62.9                      |
| Positive (≥±)                        | 24                         | 7.8                           | 19                        | 5.8                       |
| Antihypertensive drug                |                            |                               |                           |                           |
| Yes                                  | 46                         | 14.9                          | 52                        | 15.8                      |
| No                                   | 163                        | 52.8                          | 171                       | 52.0                      |
| Systolic blood pressure (mm Hg)      | 218                        | 119.9 ± 15.5                  | 226                       | 120.3 ± 16.2              |
| Diastolic blood pressure (mm Hg)     | 218                        | 74.5 ± 11.3                   | 226                       | 75.6 ± 11.2               |
| Total cholesterol (mg/dL)            | 64                         | 207.3 ± 32.0                  | 53                        | 201.7 ± 35.9              |
| Triglycerides (mg/dL)                | 217                        | 107.9 ± 64.8                  | 226                       | 101.3 ± 66.6              |

Page 14/23
| Parameter                               | Value 1   | Value 2   |
|----------------------------------------|-----------|-----------|
| HDL cholesterol (mg/dL)                | 64.6 ± 16.7 | 65.0 ± 16.9 |
| LDL cholesterol (mg/dL)                | 124.4 ± 26.9 | 126.2 ± 31.2 |
| Aspartate transaminase (U/L)          | 23.7 ± 9.3     | 23.0 ± 8.8   |
| Alanine aminotransferase (U/L)        | 23.3 ± 14.6   | 23.5 ± 13.6  |
| γ-GTP (U/L)                            | 41.4 ± 49.1   | 37.6 ± 41.6  |

**Common comorbidities**

| Condition            | Value 1 | Value 2 |
|----------------------|---------|---------|
| Hypertension         | 29.8    | 33.4    |
| Cancer               | 29.1    | 34.7    |
| Hyperlipidemia       | 28.2    | 33.7    |
| Diabetes mellitus    | 27.5    | 29.5    |
| Insomnia             | 14.2    | 13.4    |
| Liver disorder       | 13.9    | 13.4    |
| Asthma or COPD       | 13.3    | 20.1    |
| Gastrointestinal ulcer| 12.3    | 12.5    |
| Atherosclerosis or PAOD | 10.0    | 11.6    |
| Anemia               | 9.7     | 10.0    |
| Coronary artery disease | 8.4     | 10.0    |
| Heart failure        | 7.1     | 10.6    |

**Locations**

| Region     | Value 1 | Value 2 |
|------------|---------|---------|
| Hokkaido   | 2.3     | 0.9     |
| Tohoku     | 4.5     | 1.8     |
| Kanto      | 57.0    | 62.9    |
| Chubu      | 12.3    | 11.2    |
| Kinki      | 12.3    | 10.9    |
| Chugoku    | 3.2     | 2.7     |
| Areas         | N  | PDC, mean ± SD (%) | n (%) | n (%) | n (%) |
|--------------|----|--------------------|-------|-------|-------|
| Shikoku      | 2  | 0.6                | 2     | 0.6   | 2     |
| Kyushu       | 24 | 7.8                | 29    | 8.8   | 8.8   |
| East Japan   | 210| 68.0               | 220   | 66.9  |       |
| West Japan   | 99 | 32.0               | 109   | 33.1  |       |
| Tokyo and all GODMCs | 255 | 82.5               | 289   | 87.8  |       |
| Other than GODMCs | 54  | 17.5               | 40    | 12.2  |       |

HBA1c, hemoglobin A1c; NGSP, National Glycohemoglobin Standardization Program; HDL, high-density lipoprotein; LDL, low-density lipoprotein; COPD, chronic obstructive pulmonary disease; γ-GTP, γ-glutamyl transpeptidase; PAOD, peripheral arterial occlusive disease; GODMCs, government ordinance-designed major cities.

Table 2. Adherence to fixed- and unfixed-combination therapies during the 12-month post-index period

|                      | All patients | Fixed combination | Unfixed combination |
|----------------------|--------------|-------------------|---------------------|
|                      | N = 638      | N = 309           | N = 329             |
| PDC, mean ± SD (%)   | 70.4 ± 362   | 79.1 ± 32.1       | 62.2 ± 38.0         | P < 0.0001*        |
| n (%)                | n (%)        | n (%)             |                     |
| 80+% PDC             | 375 (58.8)   | 215 (69.6)        | 160 (48.6)          | P < 0.0001#        |
| <80% PDC             | 263 (41.2)   | 94 (30.4)         | 169 (51.4)          |                     |
| 60–79% PDC           | 46 (7.2)     | 16 (5.2)          | 30 (9.1)            |                     |
| 40–59% PDC           | 43 (6.7)     | 24 (7.8)          | 19 (5.8)            |                     |
| 20–39% PDC           | 54 (8.5)     | 19 (6.1)          | 35 (10.6)           |                     |
| <20% PDC             | 120 (18.8)   | 35 (11.3)         | 85 (25.8)           |                     |

PDC, proportion of days covered.

*, t-test (fixed vs. unfixed); #, \( \chi^2 \) test (fixed vs. unfixed). Note: a \( p \)-value < 0.05 / 9 (= 0.00556) was considered statistically significant (by Bonferroni correction).
Table 3. Adherence to fixed- and unfixed-combination therapies with latanoprost and timolol during the 12-month post-index period

|                    | All patients | Fixed combination | Unfixed combination |
|--------------------|--------------|-------------------|---------------------|
|                    | N = 162      | N = 123           | N = 39              |
| PDC, mean ± SD (%) | 78.9 ± 33.7  | 82.9 ± 31.1       | 66.5 ± 38.6         |
| n (%)              |              |                   |                     |
| 80+% PDC           | 114 (70.4)   | 93 (75.6)         | 21 (53.8)           |
| <80% PDC           | 48 (29.6)    | 30 (24.4)         | 18 (46.2)           |
| 60–79% PDC         | 8 (4.9)      | 6 (4.9)           | 2 (5.1)             |
| 40–59% PDC         | 9 (5.6)      | 5 (4.1)           | 4 (10.3)            |
| 20–39% PDC         | 10 (6.2)     | 7 (5.7)           | 3 (7.7)             |
| <20% PDC           | 21 (13.0)    | 12 (9.8)          | 9 (23.1)            |

PDC, proportion of days covered.

*, t-test (fixed vs. unfixed); #, χ² test (fixed vs. unfixed). Note: a p-value <0.05 / 9 (= 0.00556) was considered statistically significant (by Bonferroni correction).

Table 4. Comparison of adherences to fixed-combination therapies during the 12-month post-index period

|        | PG/BB | CAI/BB |
|--------|-------|--------|
|        | N = 241 | N = 68 |
| PDC, mean ± SD (%) | 81.2 ± 31.0 | 71.6 ± 34.9 |
| n (%) | | |
| 80+% PDC | 176 (73.0) | 39 (57.4) |
| <80% PDC | 65 (27.0) | 29 (42.6) |
| 60–79% PDC | 12 (5.0) | 4 (5.9) |
| 40–59% PDC | 15 (6.2) | 9 (13.2) |
| 20–39% PDC | 13 (5.4) | 6 (8.8) |
| <20% PDC | 25 (10.4) | 10 (14.7) |
PDC, proportion of days covered; PG, prostaglandin analogs; BB, β-blockers; CAI, carbonic anhydrase inhibitors.

*, t-test (PG/BB vs. CAI/BB); #, χ² test (PG/BB vs. CAI/BB). Note: a p-value <0.05 / 9 (= 0.00556) was considered statistically significant (by Bonferroni correction).

Table 5. Risk factors for nonadherence (PDC < 80%) to medications
| Variable                                      | Univariate | Multivariate | Odds ratio (95% CI) |
|-----------------------------------------------|------------|--------------|---------------------|
| Fixed vs. unfixed combination therapies       | <0.0001    | <0.0001      | 0.388 (0.259, 0.583) |
| Sex                                           | 0.4583     |              |                     |
| Age                                           | 0.6787     |              |                     |
| Body weight                                   | 0.9582     |              |                     |
| Height                                        | 0.4747     |              |                     |
| Body mass index                               | 0.5763     |              |                     |
| Smoking habit                                 | 0.5399     |              |                     |
| Medication for other disease                  | 0.9166     |              |                     |
| Antihypertensive drug                         | 0.6910     |              |                     |
| Fasting blood glucose                         | 0.4806     |              |                     |
| HbA1c                                         | 0.0219     | 0.0130       | 1.606 (1.105, 2.333) |
| Urine glucose                                 | 0.2091     |              |                     |
| Urine protein                                 | 0.3810     |              |                     |
| Systolic blood pressure                       | 0.3303     |              |                     |
| Diastolic blood pressure                      | 0.6046     |              |                     |
| Total cholesterol                             | 0.3382     |              |                     |
| Triglyceride                                  | 0.7453     |              |                     |
| 47 prefectures                                | >0.9999    |              |                     |
| 8 regions                                     | 0.7097     |              |                     |
| East vs. West Japan                           | 0.1569     |              |                     |
| City size                                     | 0.4610     |              |                     |
| Hypertension                                  | 0.5190     |              |                     |
| Cancer                                        | 0.3087     |              |                     |
| Hyperlipidemia                                | 0.8102     |              |                     |
| Diabetes mellitus                             | 0.4790     |              |                     |
| Insomnia                                      | 0.1181     |              |                     |
| Liver disorder                                | 0.9745     |              |                     |
Asthma or COPD 0.6839
Gastrointestinal ulcer 0.7023
Atherosclerosis or PAOD 0.8851
Anemia 0.1098
Coronary artery disease 0.4576
Heart failure 0.1229

CI, confidence interval; COPD, chronic obstructive pulmonary disease; PAOD, peripheral arterial occlusive disease; PDC, proportion of days covered.

Figures

**Figure 1**

Flowchart for data extraction

**Notes:**
- Health insurance members in 2011–2016
  - N = 4.5 million
- Patients diagnosed with glaucoma and prescribed for any IOP-lowering drug
  - N = 57,899
- Eligible patients
  - N = 19,221
- Eligible patients
  - N = 19,087
- Eligible patients
  - N = 12,306
- Fixed-combination cohort
  - N = 309
- Unfixed-combination cohort
  - N = 329
- No claims for a fixed- or unfixed-combination therapy
  - N = 38,678
- Any glaucoma surgery including laser treatment
  - N = 134
- <12 months post-index data record
  - N = 6,781
- ≤12 month pre-index period of monotherapy
  - N = 11,668

**Flowchart for data extraction IOP, intraocular pressure**
Drug class distribution of prescribed eye drops on the index date in the fixed-combination (A) and unfixed-combination (B) cohorts AA, α2-agonist; BB, β-blocker; Bim, bimatoprost; Bmn, brimonidine; Bzm, brinzolamide; CAI, carbonic anhydrase inhibitor; Car, carteolol; Dor, dorzolamide; Lat, latanoprost; PG, prostaglandin analog, Taf, tafluprost; Tim, timolol; Tra, travoprost.
Figure 3

Switching patterns from the fixed-combination (A) and unfixed-combination (B) eye drops during the 12-month post-index period AA, α2-agonist; BB, β-blocker; CAI, carbonic anhydrase inhibitor; cont’d, continued; PG, prostaglandin analog.
Figure 4

Kaplan–Meier survival curves for the treatment persistence with fixed- vs. unfixed-combination therapies (A), fixed- vs. unfixed-combination therapies with Lat and Tim (B), and fixed-combination therapies with PG and BB vs. CAI and BB (C). Bars were Hall-Wellner bands. BB, β-blocker; CAI, carbonic anhydrase inhibitor; Lat, latanoprost; PG, prostaglandin analog; Tim, timolol.